G1 Therapeutics, Inc.
Our mission is to discover, develop and deliver next generation cancer therapies.
Our mission is to discover, develop and deliver next generation cancer therapies.
G1 Therapeutics, Inc. is a commercial-stage oncology company with a goal to discover, develop and deliver next generation cancer therapies. The company is dedicated to advancing the development and commercialization of next-generation anti-cancer therapies. With a profound understanding of the biology of cancer and extensive expertise in development and commercialization, G1 aims to improve the lives of those affected by cancer. Their first commercial product, COSELA® (trilaciclib), is already in the market, and they have a robust clinical pipeline evaluating targeted cancer therapies in various solid tumors such as breast, lung, and bladder cancers. Founded in 2008, G1 Therapeutics is headquartered in Research Triangle Park, N.C. The company received a noteworthy $50.05MPost-IPO Equity investment on 17 November 2022. For more information, visit www.g1therapeutics.com and follow them on Twitter @G1Therapeutics. View their social community guidelines here.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $50.05M | - | 17 Nov 2022 | |
| Post-IPO Debt | $150.00M | - | 01 Jan 2021 | |
| Post-IPO Debt | $100.00M | 1 |
|
01 Jun 2020 |
| Post-IPO Equity | $195.10M | 1 | Cowen Investment Management | 21 Sep 2018 |
| Post-IPO Equity | $108.40M | - | 07 Mar 2018 |
No recent news or press coverage available for G1 Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
